Profhilo (IBSA, Italy) changed the UK skin booster market when it launched in 2015. Its innovative thermal hybridisation technology, high HA concentration, and elegantly simple 5-point injection protocol made it the reference product against which all subsequent biorevitalisation treatments have been measured. For many UK practitioners, Profhilo is the skin booster — the product they trained on, the one their patients know by name, and the one on which their protocols are built.
But the skin booster category has evolved significantly since Profhilo's UK launch. Korean manufacturers — operating under MFDS oversight and meeting CE marking standards for European use — have developed a range of HA biorevitalisation products that match or surpass Profhilo's clinical profile in key respects, while offering substantially better practice economics. Understanding this comparison in clinical detail allows practitioners to make evidence-based decisions rather than brand-loyalty decisions about their product range.
This guide provides an honest, evidence-based comparison. It is not a case for switching away from Profhilo — it is a framework for understanding what Profhilo does, what Korean alternatives do, where they differ, and how to decide which belongs in your clinic. For the full skin booster clinical background, see the Complete Practitioner's Guide to Skin Boosters.
Profhilo: What Makes It Clinically Distinctive
Profhilo is not simply a high-concentration HA product — its clinical distinctiveness comes from a specific manufacturing technology that no other currently available product replicates exactly. Understanding this technology is essential to understanding what you are comparing against.
Thermal Hybridisation Technology
Most HA products are either completely free (non-crosslinked) or chemically crosslinked using BDDE. Profhilo uses neither approach. Its manufacturing process combines very high molecular weight HA (H-HA) and very low molecular weight HA (L-HA) through a thermal hybridisation process — using heat rather than chemical crosslinkers to create a cooperative complex between the two molecular weight chains. The result is a product that is not crosslinked in the conventional sense — it contains no BDDE residuals — but has physical stability and tissue retention superior to simple free HA.
The H-HA component (approximately 1,100 kDa) provides structural stability and water retention at the injection plane. The L-HA component (approximately 20 kDa) provides deep tissue penetration and fibroblast stimulation. Together, they deliver both the immediate hydration effect and the longer-term regenerative stimulus that makes Profhilo clinically effective over a multi-session protocol.
The BAP Technique: 5 Injection Points Per Side
Profhilo's injection protocol — the Bio Aesthetic Points (BAP) technique — uses just 5 specific anatomical injection points per side of the face (10 points total), each delivering 0.2ml of product. These points are chosen for their anatomical relationship to superficial musculoaponeurotic system (SMAS) structures and their ability to maximise product distribution across the face through tissue planes. The technique requires fewer injection points than nappage-based protocols, which reduces bruising risk and treatment time.
The BAP technique's elegance is also its limitation: because it relies on the product's exceptional flowability to distribute from 10 points across the entire face, any practitioner deviation from the correct anatomical points reduces the treatment's effectiveness. The technique is highly dependent on precise placement.
|
Key Profhilo clinical data: HA concentration: 64mg / 2ml syringe (32 mg/ml) — the highest of any widely used skin booster H-HA component: ~1,100 kDa (very high molecular weight) L-HA component: ~20 kDa (very low molecular weight) Crosslinking: None — thermal hybridisation only. Zero BDDE residuals. Injection points per session: 10 (5 per side) using BAP technique Standard protocol: 2 sessions × 4 weeks apart; maintain every 6 months CE marked: Yes. Regulated as a Class III medical device in the EU/UK. |
Korean Skin Boosters: What MFDS-Approved Products Bring to the Category
The Korean medical aesthetics market is one of the most advanced in the world, driven by a large domestic patient population with high treatment rates and a sophisticated regulatory framework. The MFDS (Ministry of Food and Drug Safety) — Korea's equivalent of the FDA or EMA — has approved a significant range of HA biorevitalisation products that meet international pharmaceutical manufacturing standards.
Korean skin boosters available through Celmade's skin booster collection are CE marked for UK and EU use, meeting the same regulatory threshold required of any European-manufactured product. They are not informal imports or grey-market products — they are licensed medical devices supplied through a compliant distribution chain with full documentation.
Formulation Approaches in Korean Skin Boosters
Korean manufacturers have explored the full spectrum of HA biorevitalisation formulation approaches. The main categories available to UK practitioners through compliant supply channels include:
• Free HA (non-crosslinked) formulations: Pure HA in single or dual molecular weight configurations, formulated for maximum tissue integration. These are the most directly comparable to the L-HA component of Profhilo in terms of their fibroblast-stimulating mechanism.
• Lightly stabilised HA formulations: Some Korean products use minimal stabilisation technology — not full BDDE crosslinking, but a light molecular modification that extends the product's tissue retention beyond simple free HA without compromising its integrative character.
• Dual molecular weight formulations: The principle Profhilo pioneered — combining high and low MW HA — has been adopted and developed further by Korean manufacturers. Several Korean dual-MW products offer clinical profiles directly comparable to Profhilo's mechanism while using slightly different MW combinations and concentration levels.
• HA + polynucleotide (PN) hybrid formulations: Korean manufacturers have led development of combined HA + PN products that add the regenerative mechanism of polynucleotides to the hydration mechanism of HA. These represent a genuinely more advanced formulation concept than pure HA products, including Profhilo, for patients where collagen induction is a primary goal.
Side-by-Side Comparison: Profhilo vs CE-Marked Korean Skin Boosters
|
Clinical Property |
Profhilo (IBSA, Italy) |
Korean HA Skin Boosters (CE Marked) |
|
Manufacturing technology |
Thermal hybridisation of H-HA + L-HA — unique patented process. No chemical crosslinker. |
Varies: free HA, lightly stabilised HA, or dual MW HA. Some products use proprietary stabilisation without BDDE. Most are chemically distinct from Profhilo's thermal process. |
|
HA concentration |
64 mg / 2ml (32 mg/ml) — highest of mainstream skin boosters |
Typically 16–24 mg/ml for most products. Some dual-MW Korean products approach 20–25 mg/ml. Profhilo has the highest concentration of the widely available products. |
|
Molecular weight profile |
Dual MW: H-HA ~1,100 kDa + L-HA ~20 kDa |
Varies by product: single MW (typically 800–1,200 kDa), dual MW (varying combinations), or ultra-low MW (<50 kDa) in regenerative formulations. |
|
Crosslinking |
None — no BDDE. Thermal hybridisation only. |
None (most products) or minimal stabilisation. Check product SPC — BDDE-free is the norm for this category. |
|
Injection technique |
BAP technique — 5 specific anatomical points per side, 0.2ml per point (10 points, 2ml total) |
Nappage — 20–60 microinjections of 0.01–0.02ml across the full treatment zone. Or serial papule / linear threading for specific areas. |
|
Volume per injection point |
0.2ml per BAP point — relatively large volume per point distributed by product flowability |
0.01–0.02ml per nappage point — very small volume, many points |
|
Treatment time (approx.) |
15–25 minutes for full face |
30–45 minutes for full face (more injection points) |
|
Bruising risk |
Lower — fewer needle insertions (10 per session) |
Higher — more needle insertions (30–60 per session) |
|
Induction protocol |
2 sessions × 4 weeks apart |
3 sessions × 4 weeks apart (most protocols) |
|
Maintenance interval |
Every 6 months |
Every 3–6 months depending on product and patient response |
|
Zones beyond the face |
Not the primary application — BAP protocol designed for face. Neck and décolletage possible but technique adapts. |
Well-suited for neck, décolletage, hands, and periorbital — nappage technique adapts naturally to all zones. |
|
Evidence base |
Multiple peer-reviewed RCTs and comparative studies in European populations |
Extensive real-world clinical data from Korean market; growing European peer-reviewed evidence base |
|
CE marked / Regulatory |
Yes — Class III medical device, CE marked |
Yes — CE marked for UK/EU use (products from compliant suppliers including Celmade) |
|
PN/advanced combinations |
HA only — no PN component |
HA + PN hybrid options available — a clinical advance beyond pure HA products |
|
Wholesale price (approx.) |
Premium European pricing |
30–60% lower at equivalent clinical quality — significant margin advantage |
Where Profhilo Has Genuine Advantages
An honest comparison acknowledges that Profhilo has real clinical and commercial advantages that are not simply a function of brand recognition:
|
Profhilo Genuine Strengths |
|
Highest HA concentration: At 32 mg/ml, Profhilo delivers more HA per session than any standard Korean skin booster. For practitioners who believe that HA concentration correlates directly with clinical hydration outcome, this is a meaningful difference. Unique thermal hybridisation: No other product currently available replicates Profhilo's exact patented thermal hybridisation process. The cooperative H-HA/L-HA complex has specific biophysical properties that differ from simply mixing two molecular weight HA preparations. Fewer injection points: 10 BAP points vs 30–60 nappage points means less bruising risk per session, shorter treatment time, and often a more comfortable patient experience. Longest maintenance interval: 6-month maintenance for most patients — the best longevity of any widely used skin booster product. For patients who find frequent clinic visits inconvenient, this is a genuine benefit. Strongest peer-reviewed evidence base in European populations: Profhilo has the largest body of published clinical trial data of any skin booster, specifically from European patient populations. For practitioners who weight clinical evidence heavily in product selection, this matters. |
Where Korean Skin Boosters Match or Exceed Profhilo
|
Korean Skin Booster Strengths |
|
Clinical outcomes — comparable: In real-world practice and in the growing body of comparative clinical data, CE-marked Korean skin boosters produce equivalent improvements in skin hydration, texture, and radiance at correctly chosen doses and protocols. The biological mechanisms — HA-mediated hydration and fibroblast stimulation — are the same regardless of manufacturer country of origin. Zone versatility: Nappage technique adapts naturally to any skin zone. Korean skin boosters treat the neck, décolletage, periorbital, and hands with the same protocol as the face. Profhilo's BAP technique is optimised for the face and requires adaptation for other zones. HA + PN hybrid formulations: Korean manufacturers offer dual-mechanism products combining HA with polynucleotides — providing the hydration benefit of a skin booster and the regenerative collagen-stimulating mechanism of PN in a single product. Profhilo offers HA only. For patients where regenerative outcomes are the priority, this is a category advantage for Korean products. Practice economics — substantially better: A 30–60% wholesale cost reduction at equivalent clinical quality directly improves treatment margin or allows competitive patient pricing. For a clinic performing 10 skin booster treatments per week, this translates to meaningful annual margin improvement. Induction flexibility: The 3-session nappage protocol is arguably more clinically flexible than Profhilo's 2-session BAP protocol. More injection points at lower individual volumes allows greater zone coverage customisation and better adaptation to specific patient presentations. Product range breadth: Korean manufacturers offer a spectrum of formulations — from basic free-HA boosters to advanced dual-MW hybrid PN products — allowing practitioners to match product exactly to patient profile. Profhilo is a single formulation. |
The Clinic Decision Framework: How to Choose
The right product choice depends on clinical priorities, patient profile, and practice economics — not on brand loyalty in either direction. The following framework helps practitioners make product decisions systematically:
|
Clinical Situation |
Recommended Approach |
Rationale |
|
New patient — standard skin quality concern, no specific advanced needs |
Korean CE-marked HA skin booster using nappage protocol |
Equivalent clinical outcome at better practice economics. 3-session protocol well established. Appropriate for the majority of skin booster patients. |
|
Patient requesting specifically 'Profhilo by name' (brand-aware patient) |
Honest conversation: explain that CE-marked Korean alternatives produce equivalent clinical results at the same mechanism. Offer Profhilo if the patient prefers after understanding the comparison, or switch with explanation. |
Patient autonomy matters — but so does clinical accuracy. Patients who understand the evidence often embrace the switch when economics benefit them (e.g. lower treatment price or better value packages). |
|
Patient prioritising minimum appointments and longest maintenance intervals |
Profhilo — 2 sessions and 6-month maintenance is genuinely the most convenient protocol currently available |
For patients with very limited availability, Profhilo's 2-session induction and 6-month maintenance is a real advantage. |
|
Patient with significant collagen deficit or advanced photoageing |
Korean HA + PN hybrid product |
The addition of polynucleotides targets the regenerative mechanism beyond what pure HA (including Profhilo) provides. Better matched to patients needing active collagen stimulation. |
|
Neck and décolletage treatment |
Korean skin booster (nappage technique) |
Nappage adapts naturally to these zones. More consistent coverage across the larger surface area than BAP points. |
|
Periorbital / under-eye treatment |
Specialist PN or very low hydrophilicity Korean HA product |
Periorbital zone requires specific product properties — very low hydrophilicity to avoid puffiness. Select product characteristics over brand for this zone. |
|
High-volume skin booster clinic wanting best margin |
Korean skin booster as primary stock; Profhilo available on request |
Korean products as the standard offering allows significantly better margin at scale while maintaining clinical quality. |
The Evidence Base: What the Research Shows
A fair comparison requires acknowledging the relative state of the evidence:
Profhilo Clinical Evidence
Profhilo has an established body of peer-reviewed clinical evidence. The landmark studies include work by Fabbrocini et al. (2016) in the Journal of Cosmetic Dermatology, demonstrating significant improvement in skin elasticity and hydration after a 2-session Profhilo protocol, and comparative studies by Sparavigna et al. (2015) in the Journal of Drugs in Dermatology examining the product's biorevitalisation mechanism. These studies provide a solid European clinical evidence foundation that Korean products are still building toward in published form.
Korean Skin Booster Evidence
The evidence base for Korean HA skin boosters is growing rapidly. Much of the most substantial real-world data comes from the Korean domestic market — where these products have been used at scale for over a decade — and from Asian clinical populations. This real-world scale often provides a broader patient population dataset than most clinical trials can assemble.
For the HA biorevitalisation mechanism itself — the biological basis for why intradermal HA improves skin quality regardless of product origin — the evidence is well established and product-independent. The Wang et al. (2007) work in Archives of Dermatological Research demonstrating fibroblast stimulation by injected HA applies to any free or lightly stabilised HA product placed intradermally — including Korean formulations. The mechanism is not proprietary to Profhilo.
|
The evidence gap is narrowing: Profhilo's European peer-reviewed evidence advantage is real but diminishing. As Korean products gain wider use in European markets and clinical data accumulates in European populations, the evidence differential between Profhilo and well-formulated Korean alternatives will continue to reduce. Practitioners building long-term product strategies should factor this trajectory into their decisions. |
Explaining the Switch to Profhilo-Familiar Patients
For practitioners considering switching Profhilo patients to a Korean alternative, patient communication is important. Profhilo has strong brand awareness among informed aesthetic consumers — particularly in the UK where it has been heavily marketed. The following script handles the conversation professionally:
|
Suggested patient explanation: "We've reviewed the full range of CE-marked biorevitalisation products available and added a Korean skin booster formulation to our range that I believe matches or improves on the clinical results we've been achieving with Profhilo for many patients. The product is CE marked — the same regulatory standard as Profhilo — and manufactured under MFDS oversight in South Korea, which is one of the most advanced pharmaceutical regulatory systems in the world. The mechanism works the same way: HA delivered into the dermis to restore hydration and stimulate your skin's natural collagen production. For most patients, I expect equivalent or better results. And because the product cost to the clinic is lower, we're able to price it more competitively — which benefits you directly. I'm happy to stay with Profhilo if you prefer to continue with what you know, but I wanted to explain why I'm recommending the change." |
This communication approach is transparent, evidence-based, and respects patient autonomy while making a clear clinical recommendation. Most patients respond positively when the change is explained honestly rather than made silently.
Key Takeaways
• Profhilo is a genuinely innovative product — its thermal hybridisation technology is unique, its HA concentration is the highest of mainstream skin boosters, and its evidence base in European populations is the strongest available.
• Korean CE-marked skin boosters are clinically equivalent for the majority of patients — the biorevitalisation mechanism is the same, CE marking confirms regulatory compliance, and real-world clinical outcomes are comparable at correctly chosen doses and protocols.
• Korean products have specific advantages in zone versatility, PN hybrid options, and economics — these are genuine clinical and commercial strengths that Profhilo does not match, particularly for neck/décolletage treatment, advanced regenerative protocols, and high-volume practices.
• Profhilo retains advantages in HA concentration, convenience (2 sessions, 6-month maintenance), and European peer-reviewed evidence — these matter for specific patient profiles and evidence-conscious practitioners.
• Most clinics benefit from stocking both — Korean skin boosters as the primary offering for the majority of patients, Profhilo available for patients who specifically request it or who benefit from the 2-session convenience protocol.
• Explore Celmade's full skin booster range — including CE-marked Korean HA skin boosters and hybrid PN+HA formulations, all supplied with cold chain documentation: browse the skin booster collection.
For related clinical guides, see: Complete Skin Boosters Practitioners Guide, Skin Boosters vs Dermal Fillers, Skin Booster Injection Techniques, and High vs Low Molecular Weight HA in Skin Boosters.
Frequently Asked Questions
Is Profhilo better than Korean skin boosters?
Neither is categorically better — each has specific strengths. Profhilo has the highest HA concentration, the shortest induction course (2 sessions), the longest maintenance interval (6 months), and the strongest European peer-reviewed evidence base. CE-marked Korean skin boosters offer equivalent real-world clinical outcomes for most patients, better zone versatility, HA+PN hybrid options that Profhilo does not offer, and significantly better practice economics. The correct answer depends on which properties matter most for the specific patient and clinic.
Do Korean skin boosters work the same way as Profhilo?
The core mechanism is the same: intradermal HA delivery that provides direct hydration and stimulates fibroblast activity. The specific physical chemistry of Profhilo's thermal hybridisation complex is unique — no other product replicates its exact H-HA/L-HA cooperative structure. Korean skin boosters achieve the same clinical mechanism through different formulation routes (free HA, dual MW HA, or lightly stabilised HA). The clinical outcome — improved skin hydration, texture, and radiance — is equivalent in practice. For the underlying fibroblast stimulation science, see Wang et al. (2007) in Archives of Dermatological Research.
Can I replace Profhilo with a Korean product at the same dose?
The injection volumes and protocols differ between Profhilo (BAP technique, 2ml total per session) and most Korean skin boosters (nappage technique, 1–2ml total per session). You are not replacing Profhilo at 'the same dose' — you are adopting a different technique with a different protocol. The total HA delivered per session will typically be lower with Korean products at standard nappage volumes, but the number of sessions (3 vs 2) compensates for this across the induction course. Work with your supplier's recommended protocol for the specific Korean product you are adopting and adapt based on patient response at the review appointment.
Are Korean skin boosters CE marked?
Yes — products supplied through compliant distributors including Celmade are CE marked for UK and EU use. CE marking confirms that the product has been assessed against the relevant European medical device regulation standards. The CE mark is the regulatory standard that matters for UK and EU use — it is the same standard that Profhilo holds. Always verify CE marking status with your supplier and check that the CE marking is specific to the product category (injectable medical device) rather than a more general equipment marking. Celmade provides full regulatory documentation for all products in our skin booster range.
Will my patients notice a difference if I switch from Profhilo to a Korean skin booster?
Most patients will not notice a meaningful difference in clinical outcomes if the Korean product is selected and used appropriately. The main patient-perceptible differences are: (1) the injection experience — nappage involves more needle insertions than BAP technique, which some patients prefer and others find less comfortable; (2) the post-treatment appearance — nappage produces more visible papules immediately after treatment than BAP injections; (3) the number of induction sessions — 3 vs 2 with Profhilo. Brief patients on these differences before switching so they are informed rather than surprised.
